Show simple item record

dc.contributor.authorCrispín, José C.
dc.contributor.authorTsokos, George C.
dc.date.accessioned2011-03-08T19:07:53Z
dc.date.issued2010
dc.identifier.citationCrispín, José C., and George C. Tsokos. 2010. IL-17 in systemic lupus erythematosus. Journal of Biomedicine and Biotechnology 2010: 943254.en_US
dc.identifier.issn1110-7243en_US
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:4739309
dc.description.abstractIL-17 is a cytokine with powerful proinflammatory activity. Production of IL-17 is abnormally increased in patients with systemic lupus erythematosus (SLE), a multiorgan chronic autoimmune disease. In patients with SLE, CD3+CD4−CD8− (double negative) T cells are an important source of IL-17. IL-17 produced by double negative and CD4 T cells participates in the pathogenesis of the disease. IL-17-producing T cells are present in the kidneys of patients with lupus nephritis. IL-17 increased production in patients with SLE can amplify the immune response by increasing target organ inflammation and damage and by augmenting the production of antibodies by B cells.en_US
dc.language.isoen_USen_US
dc.publisherHindawi Publishing Corporationen_US
dc.relation.isversionofdoi:10.1155/2010/943254en_US
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850519/pdf/en_US
dash.licenseLAA
dc.titleIL-17 in Systemic Lupus Erythematosusen_US
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden_US
dc.relation.journalJournal of Biomedicine and Biotechnologyen_US
dash.depositing.authorTsokos, George C.
dc.date.available2011-03-08T19:07:53Z
dash.affiliation.otherHMS^Medicine- Beth Israel-Deaconessen_US
dc.identifier.doi10.1155/2010/943254*
dash.contributor.affiliatedTsokos, George


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record